Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

SLE: early-phase trial registry

5 of 10 indexed SLE trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count

SLE: 10 US clinical trials tracked, 5 recruiting.

SLE is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Stacy Ardoin MD, running 1 of these trials.

Enrollment posture brief

Registry condition sle

OPEN 5 | RECR 50% | LATE 0 | EARLY 8 | RANK #1724 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Acute Leukemia of Ambiguous 80%SLE (this)50%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near SLE

SLE lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for SLE on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. SLE is recruiting above its size-band peers.

    5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of SLE trials is spread across many organizations.

    Stacy Ardoin MD accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most SLE trials plan to enrol fewer than 100 people.

    Median target enrolment is 51 among the 10 trials that report a genuine target (sentinel values excluded). 8 of those (80%) plan for fewer than 100 participants.

  4. SLE research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 23

Open and recent trials

10 total, page 1 of 1

RECRUITING Early Phase 1 61 participants

Safety and Efficacy of ONT01 in Lupus

Hospital for Special Surgery, New York

NCT07107659

RECRUITING Phase 1 24 participants

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

Children's Hospital of Philadelphia

NCT06839976

RECRUITING Phase 1 24 participants

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

Cullinan Therapeutics

NCT06613360

RECRUITING Phase 2 24 participants

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

Ventus Therapeutics U.S.

NCT07260877

RECRUITING Phase 1 10 participants

UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients

LiveKidney.Bio

NCT06737380

ACTIVE NOT RECRUITING Phase 2 408 participants

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Alumis

NCT05966480

ACTIVE NOT RECRUITING NA 60 participants

Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases

Northwestern University

NCT05822219

ACTIVE NOT RECRUITING Phase 1 51 participants

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Artiva Biotherapeutics

NCT06265220

ACTIVE NOT RECRUITING 40 participants

Myocardial Inflammation in Systemic Lupus Erythematosus

Stacy Ardoin MD

NCT01761422

COMPLETED Phase 2 109 participants

JBT-101 in Systemic Lupus Erythematosus (SLE)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03093402

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 3

Named interventions

Most-linked intervention names on SLE records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
JBT-101 Drug
1 trials
COVID-19 vaccine and booster training, and importance Behavioral
1 trials
AB-101 Drug
1 trials
VENT-03 Drug
1 trials
Clinical laboratory evaluations - Biochemistry Diagnostic test
1 trials
Clinical laboratory evaluations - Serology Diagnostic test
1 trials
SF-36 questionnaire Other
1 trials

US sites by state

Facility locations filed on SLE trials. A trial with sites in several states counts in each.

New York 4 trials
Florida 4 trials
California 4 trials
Texas 3 trials
Tennessee 2 trials
South Carolina 2 trials
Pennsylvania 2 trials
Ohio 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this SLE page

10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This SLE condition card totals 10 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.